Ana Maria SebastiÃ£o

List of Publications by Year
in descending order

211 papers	9,543 citations	29994 54 h-index	51492 86 g-index
218 all docs	218 docs citations	218 times ranked	8824 citing authors

#	Article	IF	Citations
1	S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiology of Disease, 2022, 163, 105603.	2.1	4
2	A maestro role of adenosine A2A receptors in GABAergic synapses stabilization during postnatal neuronal maturation. Purinergic Signalling, 2022, 18, 157-159.	1.1	1
3	The Mitochondrial Antioxidant Sirtuin3 Cooperates with Lipid Metabolism to Safeguard Neurogenesis in Aging and Depression. Cells, 2022, 11, 90.	1.8	16
4	Microglia Depletion from Primary Glial Cultures Enables to Accurately Address the Immune Response of Astrocytes. Biomolecules, 2022, 12, 666.	1.8	8
5	Unexpected short- and long-term effects of chronic adolescent HU-210 exposure on emotional behavior. Neuropharmacology, 2022, 214, 109155.	2.0	7
6	Manganese dioxide nanosheet-containing reactors as antioxidant support for neuroblastoma cells. Journal of Materials Chemistry B, 2022, 10, 4672-4683.	2.9	6
7	Of adenosine and the blues: The adenosinergic system in the pathophysiology and treatment of major depressive disorder. Pharmacological Research, 2021, 163, 105363.	3.1	19
8	A New Viewpoint on the Etiopathogenesis of Depression: Insights From the Neurophysiology of Deep Brain Stimulation in Parkinson's Disease and Treatment-Resistant Depression. Frontiers in Psychiatry, 2021, 12, 607339.	1.3	7
9	Sustained NMDA receptor hypofunction impairs brain-derived neurotropic factor signalling in the PFC, but not in the hippocampus, and disturbs PFC-dependent cognition in mice. Journal of Psychopharmacology, 2021, 35, 730-743.	2.0	9
10	Adenosine Inhibits Cell Proliferation Differently in Human Astrocytes and in Glioblastoma Cell Lines. Neuroscience, 2021, 467, 122-133.	1.1	7
11	Sustained Hippocampal Neural Plasticity Questions the Reproducibility of an Amyloid-Î²-Induced Alzheimerâ€™s Disease Model. Journal of Alzheimer's Disease, 2021, 82, 1183-1202.	1.2	0
12	NLRP3 Inflammasome: A Starring Role in Amyloid-Î²- and Tau-Driven Pathological Events in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 83, 939-961.	1.2	55
13	The neurosphere assay: an effective in vitro technique to study neural stem cells. Neural Regeneration Research, 2021, 16, 2229.	1.6	13
14	Regulation of hippocampal postnatal and adult neurogenesis by adenosine <scp> A _{2A} </scp> receptor: Interaction with brainâ€derived neurotrophic factor. Stem Cells, 2021, 39, 1362-1381.	1.4	19
15	High Caloric Diet Induces Memory Impairment and Disrupts Synaptic Plasticity in Aged Rats. Current Issues in Molecular Biology, 2021, 43, 2305-2319.	1.0	8
16	Rare Diseases of Neurodevelopment: Maintain the Mystery or Use a Dazzling Tool for Investigation? The Case of Rett Syndrome. Neuroscience, 2020, 439, 146-152.	1.1	10
17	Adenosine inhibits human astrocyte proliferation independently of adenosine receptor activation. Journal of Neurochemistry, 2020, 153, 455-467.	2.1	8
18	Neural Stem Cells and Cannabinoids in the Spotlight as Potential Therapy for Epilepsy. International Journal of Molecular Sciences, 2020, 21, 7309.	1.8	1

#	Article	IF	Citations
19	Microreactors: Multicompartment Microreactors Prevent Excitotoxic Dysfunctions In Rat Primary Cortical Neurons (Adv. Biosys. 10/2020). Advanced Biology, 2020, 4, 2070102.	3.0	0
20	Caffeine has a dual influence on NMDA receptorâ€“mediated glutamatergic transmission at the hippocampus. Purinergic Signalling, 2020, 16, 503-518.	1.1	10
21	Impairment of adenosinergic system in Rett syndrome: Novel therapeutic target to boost BDNF signalling. Neurobiology of Disease, 2020, 145, 105043.	2.1	9
22	In vivo Bio-Distribution and Toxicity Evaluation of Polymeric and Lipid-Based Nanoparticles: A Potential Approach for Chronic Diseases Treatment . International Journal of Nanomedicine, 2020, Volume 15, 8609-8621.	3.3	32
23	The Neuroprotective Action of Amidated-Kyotorphin on Amyloid Î² Peptide-Induced Alzheimerâ€™s Disease Pathophysiology. Frontiers in Pharmacology, 2020, 11, 985.	1.6	9
24	Multicompartment Microreactors Prevent Excitotoxic Dysfunctions In Rat Primary Cortical Neurons. Advanced Biology, 2020, 4, e2000139.	3.0	6
25	Modeling Rett Syndrome With Human Patient-Specific Forebrain Organoids. Frontiers in Cell and Developmental Biology, 2020, 8, 610427.	1.8	49
26	Challenges of BDNF-based therapies: From common to rare diseases. Pharmacological Research, 2020, 162, 105281.	3.1	29
27	Brain-Sparing Sympathofacilitators Mitigate Obesity without Adverse Cardiovascular Effects. Cell Metabolism, 2020, 31, 1120-1135.e7.	7.2	18
28	Role of Adenosine in Epilepsy and Seizures. Journal of Caffeine and Adenosine Research, 2020, 10, 45-60.	0.8	39
29	Control of glutamate release by complexes of adenosine and cannabinoid receptors. BMC Biology, 2020, 18, 9.	1.7	51
30	Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases. Frontiers in Cellular Neuroscience, 2020, 14, 90.	1.8	145
31	From Cannabinoids and Neurosteroids to Statins and the Ketogenic Diet: New Therapeutic Avenues in Rett Syndrome?. Frontiers in Neuroscience, 2019, 13, 680.	1.4	11
32	Neurogenesis and Gliogenesis: Relevance of Adenosine for Neuroregeneration in Brain Disorders. Journal of Caffeine and Adenosine Research, 2019, 9, 129-144.	0.8	5
33	Glutamate Transporters in Hippocampal LTD/LTP: Not Just Prevention of Excitotoxicity. Frontiers in Cellular Neuroscience, 2019, 13, 357.	1.8	42
34	Memory deficits induced by chronic cannabinoid exposure are prevented by adenosine A2AR receptor antagonism. Neuropharmacology, 2019, 155, 10-21.	2.0	21
35	Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology. Molecules, 2019, 24, 1350.	1.7	28
36	TrkB-ICD Fragment, Originating From BDNF Receptor Cleavage, Is Translocated to Cell Nucleus and Phosphorylates Nuclear and Axonal Proteins. Frontiers in Molecular Neuroscience, 2019, 12, 4.	1.4	9

#	Article	IF	Citations
37	Adenosine and Its Receptors as Potential Drug Targets in Amyotrophic Lateral Sclerosis. Journal of Caffeine and Adenosine Research, 2019, 9, 157-166.	0.8	1
38	Tauroursodeoxycholic Acid Enhances Mitochondrial Biogenesis, Neural Stem Cell Pool, and Early Neurogenesis in Adult Rats. Molecular Neurobiology, 2018, 55, 3725-3738.	1.9	23
39	On the Assembly of Microreactors with Parallel Enzymatic Pathways. Advanced Biology, 2018, 2, e1700244.	3.0	14
40	Erythropoietin Induces Homeostatic Plasticity at Hippocampal Synapses. Cerebral Cortex, 2018, 28, 2795-2809.	1.6	11
41	Platinum Nanoparticle-Based Microreactors as Support for Neuroblastoma Cells. ACS Applied Materials & Interfaces, 2018, 10, 7581-7592.	4.0	20
42	Anxiety Assessment in Pre-clinical Tests and in Clinical Trials: A Critical Review. Current Topics in Medicinal Chemistry, 2018, 18, 1656-1676.	1.0	23
43	Brain-Derived Neurotrophic Factor (BDNF) Role in Cannabinoid-Mediated Neurogenesis. Frontiers in Cellular Neuroscience, 2018, 12, 441.	1.8	63
44	Adenosine A_{2A} receptors facilitate synaptic NMDA currents in CA1 pyramidal neurons. British Journal of Pharmacology, 2018, 175, 4386-4397.	2.7	31
45	GAT-3 Dysfunction Generates Tonic Inhibition in External Globus Pallidus Neurons in Parkinsonian Rodents. Cell Reports, 2018, 23, 1678-1690.	2.9	39
46	Inhibition of NMDA Receptors Prevents the Loss of BDNF Function Induced by Amyloid Î². Frontiers in Pharmacology, 2018, 9, 237.	1.6	54
47	Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors. Frontiers in Pharmacology, 2018, 9, 267.	1.6	22
48	Role of Adenosine Receptors in Epileptic Seizures. , 2018, , 309-350.		4
49	Ex vivo model of epilepsy in organotypic slicesâ€"a new tool for drug screening. Journal of Neuroinflammation, 2018, 15, 203.	3.1	33
50	Chronic, intermittent treatment with a cannabinoid receptor agonist impairs recognition memory and brain network functional connectivity. Journal of Neurochemistry, 2018, 147, 71-83.	2.1	27
51	Depression Assessment in Clinical Trials and Pre-clinical Tests: A Critical Review. Current Topics in Medicinal Chemistry, 2018, 18, 1677-1703.	1.0	35
52	Chronic and acute adenosine A2A receptor blockade prevents long-term episodic memory disruption caused by acute cannabinoid CB1 receptor activation. Neuropharmacology, 2017, 117, 316-327.	2.0	37
53	Downregulated Glia Interplay and Increased miRNA-155 as Promising Markers to Track ALS at anÂEarly Stage. Molecular Neurobiology, 2017, 55, 4207-4224.	1.9	59
54	Dissecting neurovascular coupling mechanisms: a role for adenosine A_{2A} receptor. Journal of Neurochemistry, 2017, 140, 10-12.	2.1	3

#	Article	IF	Citations
55	On the role of stigmergy in cognition. Progress in Artificial Intelligence, 2017, 6, 79-86.	1.5	5
56	VPAC₁ and VPAC₂ receptor activation on GABA release from hippocampal nerve terminals involve several different signalling pathways. British Journal of Pharmacology, 2017, 174, 4725-4737.	2.7	20
57	Enhanced LTP in aged rats: Detrimental or compensatory?. Neuropharmacology, 2017, 114, 12-19.	2.0	25
58	Influence of Adenosine on Synaptic Excitability. , 2017, , 45-76.		0
59	Interaction between Cannabinoid Type 1 and Type 2 Receptors in the Modulation of Subventricular Zone and Dentate Gyrus Neurogenesis. Frontiers in Pharmacology, 2017, 8, 516.	1.6	43
60	Dual Influence of Endocannabinoids on Long-Term Potentiation of Synaptic Transmission. Frontiers in Pharmacology, 2017, 8, 921.	1.6	25
61	Glycine Receptor Activation Impairs ATP-Induced Calcium Transients in Cultured Cortical Astrocytes. Frontiers in Molecular Neuroscience, 2017, 10, 444.	1.4	7
62	The Role of cGMP on Adenosine A1 Receptor-mediated Inhibition of Synaptic Transmission at the Hippocampus. Frontiers in Pharmacology, 2016, 7, 103.	1.6	7
63	Adenosine Kinase Deficiency in the Brain Results in Maladaptive Synaptic Plasticity. Journal of Neuroscience, 2016, 36, 12117-12128.	1.7	39
64	Dissecting striatal adenosineâ€cannabinoid receptor interactions. New clues from rats overâ€expressing adenosine A2A receptors. Journal of Neurochemistry, 2016, 136, 897-899.	2.1	3
65	Hippocampal <scp>GABA</scp>ergic transmission: a new target for adenosine control of excitability. Journal of Neurochemistry, 2016, 139, 1056-1070.	2.1	26
66	BDNF modulates glycine uptake in hippocampal synaptosomes by decreasing membrane insertion of glycine transporter 2. Neurochemistry International, 2016, 99, 94-102.	1.9	6
67	Adenosine A₁Receptor Suppresses Tonic GABA_AReceptor Currents in Hippocampal Pyramidal Cells and in a Defined Subpopulation of Interneurons. Cerebral Cortex, 2016, 26, 1081-1095.	1.6	41
68	BDNF-induced presynaptic facilitation of GABAergic transmission in the hippocampus of young adults is dependent of TrkB and adenosine A2A receptors. Purinergic Signalling, 2016, 12, 283-294.	1.1	29
69	Purine nucleosides in neuroregeneration and neuroprotection. Neuropharmacology, 2016, 104, 226-242.	2.0	61
70	Axonal elongation and dendritic branching is enhanced by adenosine A2A receptors activation in cerebral cortical neurons. Brain Structure and Function, 2016, 221, 2777-2799.	1.2	39
71	Adenosine A _{2A} receptors in neuronal outgrowth: a target for nerve regeneration?. Neural Regeneration Research, 2016, 11, 706.	1.6	5
72	BDNF, via truncated TrkB receptor, modulates GlyT1 and GlyT2 in astrocytes. Glia, 2015, 63, 2181-2197.	2.5	40

#	Article	IF	Citations
73	Neural commitment of human pluripotent stem cells under defined conditions recapitulates neural development and generates patientâ€specific neural cells. Biotechnology Journal, 2015, 10, 1578-1588.	1.8	28
74	The Combined Inhibitory Effect of the Adenosine A₁and Cannabinoid CB₁Receptors on cAMP Accumulation in the Hippocampus Is Additive and Independent of A₁Receptor Desensitization. BioMed Research International, 2015, 2015, 1-9.	0.9	10
75	MicroRNA-34a Modulates Neural Stem Cell Differentiation by Regulating Expression of Synaptic and Autophagic Proteins. Molecular Neurobiology, 2015, 51, 1168-1183.	1.9	80
76	Synaptic mechanisms of adenosine A_{2A} receptorâ€mediated hyperexcitability in the hippocampus. Hippocampus, 2015, 25, 566-580.	0.9	49
77	Neuromodulation and metamodulation by adenosine: Impact and subtleties upon synaptic plasticity regulation. Brain Research, 2015, 1621, 102-113.	1.1	60
78	Differential Role of the Proteasome in the Early and Late Phases of BDNF-Induced Facilitation of LTP. Journal of Neuroscience, 2015, 35, 3319-3329.	1.7	40
79	Neuroinflammation after neonatal hypoxiaâ€“ischemia is associated with alterations in the purinergic system: adenosine deaminase 1 isoenzyme is the most predominant after insult. Molecular and Cellular Biochemistry, 2015, 403, 169-177.	1.4	8
80	Adenosine A2A receptor activation is determinant for BDNF actions upon GABA and glutamate release from rat hippocampal synaptosomes. Purinergic Signalling, 2015, 11, 607-612.	1.1	23
81	Presymptomatic and symptomatic ALS SOD1(G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission. Purinergic Signalling, 2015, 11, 471-480.	1.1	24
82	Brain-derived neurotrophic factor mediates neuroprotection against AÎ²-induced toxicity through a mechanism independent on adenosine 2A receptor activation. Growth Factors, 2015, 33, 298-308.	0.5	14
83	Dysregulation of TrkB Receptors and BDNF Function by Amyloid-Î² Peptide is Mediated by Calpain. Cerebral Cortex, 2015, 25, 3107-3121.	1.6	84
84	The giant miniature endplate potentials frequency is increased in aged rats. Neuroscience Letters, 2015, 584, 224-229.	1.0	12
85	Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinsonâ€™s Disease. Current Topics in Neurotoxicity, 2015, , 57-79.	0.4	1
86	Adenosine A2A Receptors Activation Facilitates Neuromuscular Transmission in the Pre-Symptomatic Phase of the SOD1(G93A) ALS Mice, but Not in the Symptomatic Phase. PLoS ONE, 2014, 9, e104081.	1.1	31
87	Mechanisms of Regulation of Olfactory Transduction and Adaptation in the Olfactory Cilium. PLoS ONE, 2014, 9, e105531.	1.1	15
88	Modulation of subventricular zone oligodendrogenesis: a role for hemopressin?. Frontiers in Cellular Neuroscience, 2014, 8, 59.	1.8	22
89	Homeostatic plasticity induced by brief activity deprivation enhances long-term potentiation in the mature rat hippocampus. Journal of Neurophysiology, 2014, 112, 3012-3022.	0.9	23
90	Modulation of cGMP accumulation by adenosine A1 receptors at the hippocampus: Influence of cGMP levels and gender. European Journal of Pharmacology, 2014, 744, 83-90.	1.7	5

#	Article	IF	Citations
91	Modeling the functional network of primary intercellular Ca2+ wave propagation in astrocytes and its application to study drug effects. Journal of Theoretical Biology, 2014, 356, 201-212.	0.8	12
92	Impact of inÂvivo chronic blockade of adenosine A2A receptors on the BDNF-mediated facilitation of LTP. Neuropharmacology, 2014, 83, 99-106.	2.0	31
93	Regulation of TrkB receptor translocation to lipid rafts by adenosine A2A receptors and its functional implications for BDNF-induced regulation of synaptic plasticity. Purinergic Signalling, 2014, 10, 251-267.	1.1	36
94	P2Y‹sub›1‹/sub›receptor inhibits GABA transport through a calcium signalling-dependent mechanism in rat cortical astrocytes. Glia, 2014, 62, 1211-1226.	2.5	45
95	Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinsonâ€™s Disease. Drugs and Aging, 2014, 31, 239-261.	1.3	25
96	Maternal separation impairs long term-potentiation in CA1-CA3 synapses and hippocampal-dependent memory in old rats. Neurobiology of Aging, 2014, 35, 1680-1685.	1.5	79
97	Adenosine A2A Receptors as novel upstream regulators of BDNF-mediated attenuation of hippocampal Long-Term Depression (LTD). Neuropharmacology, 2014, 79, 389-398.	2.0	23
98	Homeostatic Control of Synaptic Activity by Endogenous Adenosine is Mediated by Adenosine Kinase. Cerebral Cortex, 2014, 24, 67-80.	1.6	54
99	GlyT1 and GlyT2 in brain astrocytes: expression, distribution and function. Brain Structure and Function, 2014, 219, 817-830.	1.2	32
100	Hypoxiaâ€“Ischemia Alters Nucleotide and Nucleoside Catabolism and Na+,K+-ATPase Activity in the Cerebral Cortex of Newborn Rats. Neurochemical Research, 2013, 38, 886-894.	1.6	15
101	A1Râ€“A2AR heteromers coupled to Gs and Gi/0 proteins modulate GABA transport into astrocytes. Purinergic Signalling, 2013, 9, 433-449.	1.1	123
102	Tauroursodeoxycholic acid suppresses amyloid Î²-induced synaptic toxicity in vitro and in APP/PS1 mice. Neurobiology of Aging, 2013, 34, 551-561.	1.5	44
103	Ischemia-induced synaptic plasticity drives sustained expression of calcium-permeable AMPA receptors in the hippocampus. Neuropharmacology, 2013, 65, 114-122.	2.0	39
104	Adenosine A2A receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation. Molecular Psychiatry, 2013, 18, 320-331.	4.1	124
105	Adenosine: setting the stage for plasticity. Trends in Neurosciences, 2013, 36, 248-257.	4.2	112
106	Lipid rafts, synaptic transmission and plasticity: Impact in age-related neurodegenerative diseases. Neuropharmacology, 2013, 64, 97-107.	2.0	102
107	Caffeine and Adenosine Receptor Modulation of Cannabinoid Influence Upon Cognitive Function. Journal of Caffeine Research, 2013, 3, 85-95.	1.0	3
108	Activation of Type 1 Cannabinoid Receptor (CB1R) Promotes Neurogenesis in Murine Subventricular Zone Cell Cultures. PLoS ONE, 2013, 8, e63529.	1.1	67

#	Article	IF	Citations
109	Early Changes of Neuromuscular Transmission in the SOD1(G93A) Mice Model of ALS Start Long before Motor Symptoms Onset. PLoS ONE, 2013, 8, e73846.	1.1	131
110	Downstream Pathways of Adenosine. , 2013, , 131-156.		3
111	From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications. CNS and Neurological Disorders - Drug Targets, 2012, 11, 652-663.	0.8	7
112	Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiology of Aging, 2012, 33, 1122.e23-1122.e39.	1.5	81
113	Neuromuscular transmission modulation by adenosine upon aging. Neurobiology of Aging, 2012, 33, 2869-2880.	1.5	11
114	Neuritic growth impairment and cell death by unconjugated bilirubin is mediated by NO and glutamate, modulated by microglia, and prevented by glycoursodeoxycholic acid and interleukin-10. Neuropharmacology, 2012, 62, 2398-2408.	2.0	63
115	Extracellular Alpha-Synuclein Oligomers Modulate Synaptic Transmission and Impair LTP Via NMDA-Receptor Activation. Journal of Neuroscience, 2012, 32, 11750-11762.	1.7	228
116	Spintronic platforms for biomedical applications. Lab on A Chip, 2012, 12, 546-557.	3.1	112
117	Neuroprotection afforded by adenosine A_{2A} receptor blockade is modulated by corticotrophinâ€releasing factor (<scp>CRF</scp>) in glutamate injured cortical neurons. Journal of Neurochemistry, 2012, 123, 1030-1040.	2.1	26
118	Enhancement of AMPA currents and GluR1 membrane expression through PKAâ€coupled adenosine A_{2A} receptors. Hippocampus, 2012, 22, 276-291.	0.9	76
119	Dopamineâ€“Galanin Receptor Heteromers Modulate Cholinergic Neurotransmission in the Rat Ventral Hippocampus. Journal of Neuroscience, 2011, 31, 7412-7423.	1.7	31
120	Modulation of GABA Transport by Adenosine A1R-A2AR Heteromers, Which Are Coupled to Both Gs- and Gi/o-Proteins. Journal of Neuroscience, 2011, 31, 15629-15639.	1.7	16
121	Modulation of brain-derived neurotrophic factor (BDNF) actions in the nervous system by adenosine A2A receptors and the role of lipid rafts. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1340-1349.	1.4	47
122	Brain-derived Neurotrophic Factor (BDNF) Enhances GABA Transport by Modulating the Trafficking of GABA Transporter-1 (GAT-1) from the Plasma Membrane of Rat Cortical Astrocytes. Journal of Biological Chemistry, 2011, 286, 40464-40476.	1.6	59
123	Ageâ€related changes of glycine receptor at the rat hippocampus: from the embryo to the adult. Journal of Neurochemistry, 2011, 118, 339-353.	2.1	48
124	Neuronal ENT1 takes up synaptic adenosine even under hypoxia/ischemia. Journal of Neurochemistry, 2011, 118, 1-3.	2.1	2
125	Enhancement of LTP in Aged Rats is Dependent on Endogenous BDNF. Neuropsychopharmacology, 2011, 36, 1823-1836.	2.8	117
126	Adenosine and Related Drugs in Brain Diseases: Present and Future in Clinical Trials. Current Topics in Medicinal Chemistry, 2011, 11, 1087-1101.	1.0	87

#	Article	IF	Citations
127	Regulation of Hippocampal Cannabinoid CB1 Receptor Actions by Adenosine A1 Receptors and Chronic Caffeine Administration: Implications for the Effects of Î”9-Tetrahydrocannabinol on Spatial Memory. Neuropsychopharmacology, 2011, 36, 472-487.	2.8	48
128	Adenosine and epilepsyâ€”thinking beyond A1 receptors. Purinergic Signalling, 2010, 6, 1-2.	1.1	3
129	Interleukinâ€6â€type cytokines in neuroprotection and neuromodulation: oncostatin M, but not leukemia inhibitory factor, requires neuronal adenosine A₁ receptor function. Journal of Neurochemistry, 2010, 114, 1667-1677.	2.1	32
130	Modulation and metamodulation of synapses by adenosine. Acta Physiologica, 2010, 199, 161-169.	1.8	54
131	Activation of Adenosine A2A Receptors Induces TrkB Translocation and Increases BDNF-Mediated Phospho-TrkB Localization in Lipid Rafts: Implications for Neuromodulation. Journal of Neuroscience, 2010, 30, 8468-8480.	1.7	50
132	Predominance of Adenosine Excitatory over Inhibitory Effects on Transmission at the Neuromuscular Junction of Infant Rats. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 153-163.	1.3	25
133	Caffeine and Adenosine. Journal of Alzheimer's Disease, 2010, 20, S3-S15.	1.2	360
134	Adenosine A3 Receptor Signaling in the Central Nervous System. , 2010, , 165-188.		5
135	Tuning and Fine-Tuning of Synapses with Adenosine. Current Neuropharmacology, 2009, 7, 180-194.	1.4	93
136	Cannabinoid CB1 and adenosine A1 receptors independently inhibit hippocampal synaptic transmission. European Journal of Pharmacology, 2009, 623, 41-46.	1.7	27
137	Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection. British Journal of Pharmacology, 2009, 158, 15-22.	2.7	61
138	GDNF control of the glutamatergic corticoâ€striatal pathway requires tonic activation of adenosine A_{2A} receptors. Journal of Neurochemistry, 2009, 108, 1208-1219.	2.1	33
139	Adenosine A2A receptors enhance GABA transport into nerve terminals by restraining PKC inhibition of GATâ€1. Journal of Neurochemistry, 2009, 109, 336-347.	2.1	52
140	Adenosine Receptors and the Central Nervous System. Handbook of Experimental Pharmacology, 2009, , 471-534.	0.9	204
141	Adenosine A2A Receptor Modulation of Hippocampal CA3-CA1 Synapse Plasticity During Associative Learning in Behaving Mice. Neuropsychopharmacology, 2009, 34, 1865-1874.	2.8	82
142	Brain-derived neurotrophic factor inhibits GABA uptake by the rat hippocampal nerve terminals. Brain Research, 2008, 1219, 19-25.	1.1	33
143	A1 and A2A receptor activation by endogenous adenosine is required for VIP enhancement of K+-evoked [3H]-GABA release from rat hippocampal nerve terminals. Neuroscience Letters, 2008, 430, 207-212.	1.0	23
144	Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology, 2008, 54, 924-933.	2.0	120

#	Article	IF	Citations
145	Interleukin-6 Upregulates Neuronal Adenosine A1 Receptors: Implications for Neuromodulation and Neuroprotection. Neuropsychopharmacology, 2008, 33, 2237-2250.	2.8	63
146	Postsynaptic Action of Brain-Derived Neurotrophic Factor Attenuates Â7 Nicotinic Acetylcholine Receptor-Mediated Responses in Hippocampal Interneurons. Journal of Neuroscience, 2008, 28, 5611-5618.	1.7	41
147	Tonic adenosine A1 and A2A receptor activation is required for the excitatory action of VIP on synaptic transmission in the CA1 area of the hippocampus. Neuropharmacology, 2007, 52, 313-320.	2.0	18
148	Influence of age on BDNF modulation of hippocampal synaptic transmission: Interplay with adenosine A2A receptors. Hippocampus, 2007, 17, 577-585.	0.9	85
149	Triggering of BDNF facilitatory action on neuromuscular transmission by adenosine A2A receptors. Neuroscience Letters, 2006, 404, 143-147.	1.0	60
150	VPAC2 Receptor Activation Mediates VIP Enhancement of Population Spikes in the CA1 Area of the Hippocampus. Annals of the New York Academy of Sciences, 2006, 1070, 210-214.	1.8	11
151	Nitric oxide mediates interactions between GABAA receptors and adenosine A1 receptors in the rat hippocampus. European Journal of Pharmacology, 2006, 543, 32-39.	1.7	13
152	Glial cell line-derived neurotrophic factor (GDNF) enhances dopamine release from striatal nerve endings in an adenosine A2A receptor-dependent manner. Brain Research, 2006, 1113, 129-136.	1.1	38
153	Adenosine A 2A receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus. Journal of Neurochemistry, 2005, 93, 595-604.	2.1	79
154	VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors. Brain Research, 2005, 1049, 52-60.	1.1	30
155	Activation of Adenosine A2A Receptor Facilitates Brain-Derived Neurotrophic Factor Modulation of Synaptic Transmission in Hippocampal Slices. Journal of Neuroscience, 2004, 24, 2905-2913.	1.7	161
156	VIP enhances both pre- and postsynaptic GABAergic transmission to hippocampal interneurones leading to increased excitatory synaptic transmission to CA1 pyramidal cells. British Journal of Pharmacology, 2004, 143, 733-744.	2.7	37
157	Brain-derived neurotrophic factor facilitates glutamate and inhibits GABA release from hippocampal synaptosomes through different mechanisms. Brain Research, 2004, 1016, 72-78.	1.1	41
158	Endogenous adenosine modulation of 22Na uptake by rat brain synaptosomes. Neurochemical Research, 2003, 28, 1591-1595.	1.6	2
159	Enhanced Adenosine A2A Receptor Facilitation of Synaptic Transmission in the Hippocampus of Aged Rats. Journal of Neurophysiology, 2003, 90, 1295-1303.	0.9	97
160	Participation of adenosine receptors in neuroprotection. Drug News and Perspectives, 2003, 16, 80.	1.9	77
161	Effects of Carbamazepine and Novel 10,11-Dihydro-5H -Dibenz[b,f]Azepine-5-Carboxamide Derivatives on Synaptic Transmission in Rat Hippocampal Slices. Basic and Clinical Pharmacology and Toxicology, 2002, 90, 208-213.	0.0	17
162	Pertussis toxin-sensitive G proteins mediate the inhibition of basal phosphoinositide metabolism caused by adenosine A1 receptors in rat hippocampal slices. Neurochemical Research, 2002, 27, 1707-1711.	1.6	8

#	Article	IF	Citations
163	Activation of Synaptic NMDA Receptors by Action Potential-Dependent Release of Transmitter during Hypoxia Impairs Recovery of Synaptic Transmission on Reoxygenation. Journal of Neuroscience, 2001, 21, 8564-8571.	1.7	89
164	Neuroprotection during hypoxic insults: Role of adenosine. Drug Development Research, 2001, 52, 291-295.	1.4	10
165	Adenosine receptor interactions in the hippocampus. Drug Development Research, 2001, 52, 337-345.	1.4	10
166	Modification of adenosine modulation of synaptic transmission in the hippocampus of aged rats. British Journal of Pharmacology, 2000, 131, 1629-1634.	2.7	83
167	Adenosine: does it have a neuroprotective role after all?. Brain Research Reviews, 2000, 33, 258-274.	9.1	224
168	Fine-tuning neuromodulation by adenosine. Trends in Pharmacological Sciences, 2000, 21, 341-346.	4.0	237
169	Chapter 15 Adenine nucleotides as inhibitors of synaptic transmission: Role of localised ectonucleotidases. Progress in Brain Research, 1999, 120, 183-192.	0.9	22
170	An Adenosine Analogue Inhibits NMDA Receptor-Mediated Responses in Bipolar Cells of the Rat Retina. Experimental Eye Research, 1999, 68, 367-370.	1.2	26
171	Adenosine A₁ Receptor Activation Inhibits Basal Accumulation of Inositol Phosphates in Rat Hippocampus. Basic and Clinical Pharmacology and Toxicology, 1998, 82, 189-192.	0.0	11
172	Inhibition by ATP of Hippocampal Synaptic Transmission Requires Localized Extracellular Catabolism by Ecto-Nucleotidases into Adenosine and Channeling to Adenosine A₁Receptors. Journal of Neuroscience, 1998, 18, 1987-1995.	1.7	207
173	Biological activities of N6,C8-disubstituted adenosine derivatives as partial agonists at rat brain adenosine A1 receptors. European Journal of Pharmacology, 1997, 334, 299-307.	1.7	14
174	On the High Affinity of 8â€Cyclohexylcaffeine for the Presynaptic Inhibitory Adenosine Receptor Present in Rat Motor Nerve Terminals. Basic and Clinical Pharmacology and Toxicology, 1997, 80, 295-300.	0.0	1
175	Chapter 23 Purinergic regulation of acetylcholine release. Progress in Brain Research, 1996, 109, 231-241.	0.9	66
176	Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. British Journal of Pharmacology, 1996, 119, 253-260.	2.7	147
177	Calcitonin Gene-Related Peptide in the Hamster Seminal Vesicle and Coagulating Gland: An Immunohistochemical, Autoradiographical, and Pharmacological Study. Peptides, 1996, 17, 1189-1195.	1.2	10
178	Adenosine by activating A1 receptors prevents GABAA-mediated actions during hypoxia in the rat hippocampus. Brain Research, 1996, 732, 261-266.	1.1	31
179	Purinoceptors and synaptic plasticity. Drug Development Research, 1996, 39, 353-360.	1.4	4
180	Preferential Release of ATP and Its Extracellular Catabolism as a Source of Adenosine upon Highâ€•but Not Lowâ€Frequency Stimulation of Rat Hippocampal Slices. Journal of Neurochemistry, 1996, 67, 2180-2187.	2.1	232

#	Article	IF	Citations
181	Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. NeuroReport, 1995, 6, 1097-1100.	0.6	153
182	Modification of A-i and A2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. NeuroReport, 1995, 6, 1583.	0.6	141
183	Ascorbate/Fe3+-induced peroxidation and inhibition of the binding of A1 adenosine receptor ligands in rat brain membranes. Neurochemistry International, 1995, 26, 263-268.	1.9	8
184	Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neuroscience Letters, 1995, 196, 41-44.	1.0	74
185	Role of A2a Receptors in the Hippocampus and Motor Nerve Endings. , 1995, , 251-261.		1
186	Purinergic Modulation of the Evoked Release of [3H]Acetylcholine from the Hippocampus and Cerebral Cortex of the Rat: Role of the Ectonucleotidases. European Journal of Neuroscience, 1994, 6, 33-42.	1.2	61
187	Excitatory and Inhibitory Effects of A₁ and A_{2A} Adenosine Receptor Activation on the Electrically Evoked [³H]Acetylcholine Release from Different Areas of the Rat Hippocampus. Journal of Neurochemistry, 1994, 63, 207-214.	2.1	141
188	Adenosine and adenine nucleotides are independently released from both the nerve terminals and the muscle fibres upon electrical stimulation of the innervated skeletal muscle of the frog. Pflugers Archiv European Journal of Physiology, 1993, 424, 503-510.	1.3	89
189	On the high affinity binding site for [³H]â€1,3â€dipropylâ€8â€cyclopentylxanthine in frog brain membranes. British Journal of Pharmacology, 1993, 109, 518-523.	2.7	7
190	Evidence for the presence of excitatory A2 adenosine receptors in the rat hippocampus. Neuroscience Letters, 1992, 138, 41-44.	1.0	121
191	Adenine nucleotide analogues, including Î³-phosphate-substituted analogues, are metabolised extracellularly in innervated frog sartorius muscle. European Journal of Pharmacology, 1992, 222, 49-59.	1.7	27
192	Ecto-5'-Nucleotidase Is Associated with Cholinergic Nerve Terminals in the Hippocampus but Not in the Cerebral Cortex of the Rat. Journal of Neurochemistry, 1992, 59, 657-666.	2.1	82
193	Inhibitory and excitatory effects of adenosine receptor agonists on evoked transmitter release from phrenic nerve endings of the rat. British Journal of Pharmacology, 1991, 103, 1614-1620.	2.7	128
194	Extracellular metabolism of adenine nucleotides and adenosine in the innervated skeletal muscle of the frog. European Journal of Pharmacology, 1991, 197, 83-92.	1.7	61
195	Solubilized Rat Brain Adenosine Receptors Have Two High-Affinity Binding Sites for l, 3-Dipropyl-8-Cyclopentylxanthine. Journal of Neurochemistry, 1991, 57, 1165-1171.	2.1	17
196	Relative Contribution of Nerve Endings to the Release of Adenine Nucleotides in the Innervated from Sartorius Muscle. Nucleosides & Nucleotides, 1991, 10, 1189-1190.	0.5	1
197	Effect of 5'-(N-Ethylcarboxamido)adenosine on Adenosine Transport in Cultured Chromaffin Cells. Journal of Neurochemistry, 1990, 54, 1941-1946.	2.1	33
198	Interactions between adenosine and phorbol esters or lithium at the frog neuromuscular junction. British Journal of Pharmacology, 1990, 100, 55-62.	2.7	36

#	Article	IF	Citations
199	The inhibitory adenosine receptor at the neuromuscular junction and hippocampus of the rat: antagonism by 1,3,8â€substituted xanthines. British Journal of Pharmacology, 1990, 101, 453-459.	2.7	88
200	Separation of adenosine triphosphate and its degradation products in innervated muscle of the frog by reverse phase high-performance liquid chromatography. Chromatographia, 1989, 28, 610-612.	0.7	25
201	1,3,8â€•and 1,3,7â€substituted xanthines: relative potency as adenosine receptor antagonists at the frog neuromuscular junction. British Journal of Pharmacology, 1989, 96, 211-219.	2.7	37
202	N6-Cyclohexyladenosine Inhibits Veratridine-Stimulated Na Uptake by Rat Brain Synaptosomes. Journal of Neurochemistry, 1988, 50, 899-903.	2.1	7
203	Is inhibition of neurotransmitter release mediated by A3 receptors? Subtypes of adenosine receptors. Trends in Pharmacological Sciences, 1988, 9, 279-280.	4.0	7
204	On the adenosine receptor and adenosine inactivation at the rat diaphragm neuromuscular junction. British Journal of Pharmacology, 1988, 94, 109-120.	2.7	51
205	On the role, inactivation and origin of endogenous adenosine at the frog neuromuscular junction.. Journal of Physiology, 1987, 384, 571-585.	1.3	135
206	Inhibitory effects of forskolin and papaverine on nerve conduction partially blocked by tetrodotoxin in the frog sciatic nerve. British Journal of Pharmacology, 1985, 85, 309-313.	2.7	7
207	On the type of receptor involved in the inhibitory action of adenosine at the neuromuscular junction. British Journal of Pharmacology, 1985, 84, 911-918.	2.7	45
208	Enhancement of transmission at the frog neuromuscular junction by adenosine deaminase: Evidence for an inhibitory role of endogenous adenosine on neuromuscular transmission. Neuroscience Letters, 1985, 62, 267-270.	1.0	31
209	Antagonism of tetrodotoxinâ€•and procaineâ€induced axonal blockade by adenine nucleotides in the frog sciatic nerve. British Journal of Pharmacology, 1984, 81, 277-282.	2.7	16
210	Enhancement of tetrodotoxinâ€induced axonal blockade by adenosine, adenosine analogues, dibutyryl cyclic AMP and methylxanthines in the frog sciatic nerve. British Journal of Pharmacology, 1984, 83, 485-492.	2.7	27
211	Astrocytes in Amyotrophic Lateral Sclerosis. , 0, , 35-54.		7